Monday, August 15, 2022

mRNA technology key to making personalized medicine in US or cancer – Medical Gazette

Scientific advances made in recent years – at an alarming pace and, above all, driven by the COVID-19 pandemic – may seem like something out of a movie. And yet they are more real than ever. ,This is science, not fiction, A phrase that gave Pfizer its name for the first informational meeting where a different perspective on the present and future of research was shown.

The company is now world renowned for its progress messenger RNA, with which it has achieved a safe and effective vaccine against COVID-19 in record time. But, as mentioned Sergio RodriguezThe rapid development and launch of the first vaccine against COVID-19 “would not have been possible without previous years of research into this new technology that could offer many promising possibilities in the future”, director general of Pfizer Spain. “Thanks for this technique” We will go further in tackling infectious diseases, rare diseases or even cancerRodriguez added.

precision medicine

“To talk about mRNA is to talk about innovation and a technological revolution that is as promising as genomic medicine and precision medicine,” he explained. maite hernandezPfizer Communications Director for Southern Europe.

Precisely, personalized precision medicine was the focus on which he focused his intervention. Angel Maria CarracedoCoordinator of the Genomic Medicine Group at the University of Santiago de Compostela (CIBERER) and Professor of Pathological Anatomy and Forensic Sciences at the University of Santiago de Compostela.

Carracedo defines precision medicine as “needed”Break something complicated into groups where drugs may be more effective“. And that is, one of the challenges of the industry is that “it’s getting harder to get better medicine out there”, because the disease is so heterogeneous. Thus, there is a need to “divide” the disease into its components. The probability is important, that is, stratification disease,

Similarly, personalized medicine seeks a way of knowing which people are likely to respond well to a drug or treatment and which are likely to be adversely affected. Therefore, his goal is to “use something that marks what we call” biomarkersCarracado indicated. In this way, personalized medicine is based on biomarkers, is generally genomic, and is Three stages of development:

  1. The discovery, research, and identification of biomarkers that allow disease to be divided into groups where drugs are more effective or biomarkers of response to drugs or treatments.
  2. Regulatory approval of the drug.
  3. translate.
Read Also:  ADHD: Identifies symptoms that persist into adulthood

“The first phase made a lot of progress in the genomic part, thanks to two types of technology. There is a very important new generation sequence, that is, read DNA“, assured Carracedo. Thus, there are three main areas of application of precision medicine or genomic medicine:

  • rare disease, Thanks for the technology, EE. RR. -which are mostly genetic diseases- they can be sequenced and diagnosed faster and faster. “We have to go further, because the hopefuls are to be able to diagnose them in a year from the symptoms. In Spain we have an average of over 3 years”, said Carracedo, who attributed this to a characteristic lack of clinical genetics in the country. “Currently, there are over 200 approved RRSE treatments and It is estimated that there will be 2,000 by 2027,” he said.
  • cancer, “The International Cancer Genome Project allowed us to discover a panorama of mutations affecting different types of cancer and, along with advances in immunology, allowed targeted therapies, CAR-T, which is a major advance in cancer survival. represents”, emphasized. expert. Most cancer treatments today are personalized, linked with biomarkers.
  • pharmacogenetics, “In half of the drugs we have, there are indications on the technical sheets that indicate whether it’s appropriate for that person,” explained Carracedo.

In what sense, Spain has certainly opted for personalized medicine, proof of this is the beginning personalized medicine strategy, is closely linked to Vanguard Health PERTE. It has also created a huge infrastructure to develop this personalized medicine, through ISCIII (influence), which has three areas: “a national follow-up group that Spain lacked, a second data program and a genomic medicine program,” Carracedo said.

The future of mRNA beyond COVID-19

The future of mRNA is promising, yes. But what can its potential be used for? Uwe SchonbeckScientific director, external research and development innovation and Pfizer’s senior vice president of worldwide research and development, assured that the company’s focus is aimed at moving forward in several specific areas.

On the one hand, Schönbeck hit the target of Continue investing in research on vaccines, such as COVID-19“Not only allows access to vaccines for the younger population (recently approved for children under the age of 5), but continues with booster dose strategies with optimization of all types of vaccine and which we Constantly say covid”.

Read Also:  Building stronger cooperation to "attack" future pandemics

In addition, Pfizer has Expanding your R&D portfolio with other vaccines such as flu or herpes zoster (HZ), “At Influenza we have a modified mRNA format and an enhanced one to determine which of them may provide the greatest benefit for a vaccine. Our goal is to develop a vaccine that protects against all types of strains. can save and Higher efficacy than current vaccinesSchonbeck explained. At the moment, there is no seasonal flu vaccine that allows such complete coverage.

For HZ, this is another example where the company believes that mRNA can be used for new therapies. “We look forward to developing a vaccine that is highly efficacious, with excellent tolerability and provide better benefits for patients,” he said.

Another area where they want to apply mRNA is in the ER, where it can “correct a genetic defect”. ,In rare diseases, this technique has great potential for success., We are following and monitoring investments in mRNA design and administration to optimize all technical aspects”, revealed Schönbeck.

Coalition, a pillar for Pfizer

“One of the Pillars on Which” Our culture of innovation is alignedDeclared the CEO of Pfizer Spain. “We know that innovation cannot depend exclusively on our internal capability or on individual teams. thus, We work in collaboration with scientific institutions, governments, patient associations, biotech companiese.t.c. “They said. For Rodriguez, patients are the “primary focus” and at Pfizer they are committed to engaging more and more throughout the research process.

In fact, “with success and development, through the pandemic” Alliance with BioNTechhas established the power of mRNA technology,” said Uwe Schoenbeck. “We have emerged as One of the leaders in the mRNA space And we continue to invest heavily in this area. Being a pioneer in a cutting-edge field, such as mRNA, is there to transfer knowledge and see where there is more potential”, he assured.

“In short, cutting-edge researchCollaboration with the agents involved and achieving patients’ well-being guides our science, and this is not fiction”, concluded Sergio Rodriguez.


You may also like…

Nation World News Desk
Nation World News Deskhttps://nationworldnews.com
Nation World News is the fastest emerging news website covering all the latest news, world’s top stories, science news entertainment sports cricket’s latest discoveries, new technology gadgets, politics news, and more.
Latest news
Related news
- Advertisement -